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Cutaneous T cell lymphomas are considered to
represent a clonal malignancy of mature T lympho-
cytes of the T helper memory subtype. A method
enabling the direct identi®cation of clonal malignant
cells in tissue and, at the same time, identi®cation of
the surface molecules they express has not been
available, however. We have developed an applica-
tion of the FICTION technique (simultaneous ¯uor-
escence immunophenotyping and interphase
cytogenetics) to be used on fresh blood, skin, and
lymph node samples. A prerequisite for this method
is the characterization of a moleculocytogenetic
clone in order to select the proper probes. With this
method, we demonstrate that the true malignant
cells express CD3, CD4, and CD45RO in the blood,
skin, and lymph nodes of two Sezary syndrome
patients. The majority of these cells express also
CD45RA (albeit of varying intensity) and CDw150.
The cytokine expression pattern of the clonal cells in
skin and lymph nodes was interleukin-2 and inter-
feron-g negative and interleukin-4 positive.
Interleukin-10 expression varied. The malignant cells
did not express granzyme B, thus indicating that
they do not have cytotoxic properties. Clonal cells
with the same constant phenotype could be found
even in lymph nodes with not yet morphologically
identi®able malignant cells. This is the ®rst report of
the FICTION method applied directly on skin tissue.
With this method we demonstrated that the chromo-
somally clonal cells in these two cases of Sezary syn-
drome could be intermediate forms between naõÈve
CD45RA+ and CD45RO+ Th2 cells. Key words:
CD45/CDw150/cutaneous T cell lymphoma/extracuta-
neous. J Invest Dermatol 116:188±193, 2001
I
n order to understand the pathomechanism and biology of
primary cutaneous T cell lymphomas (CTCLs), the
phenotype and function of the malignant cells in various
compartments of the body should be known. The malignant
lymphocytes in most CTCLs are considered to represent a
malignancy of mature T lymphocytes of the T helper memory
subtype (Haynes et al, 1981; Ralfkiaer, 1991). Previous studies of
the phenotype of these cells have been based on morphologic
identi®cation of the malignant cells or on ¯ow cytometric
identi®cation of clonal T cell receptor (TCR) a, b, or g locus
rearrangement1 (Haynes et al, 1981; Longley et al, 1995; Dummer
et al, 1996; Bakels et al, 1997; Bagot et al, 1998). Based on
functional in vitro assays of peripheral blood mononuclear cells,
Sezary syndrome (SS), the leukemic subtype of CTCL, has been
suggested to present the Th2-type T cell pro®le whereas mycosis
fungoides (MF) would represent a Th1-type pro®le (Vowels et al,
1992; Saed et al, 1994; Dummer et al, 1996). These methods may
not always have identi®ed speci®cally the true malignant cells,
however, as the CTCL lesions also contain clonal T cells reacting
against the tumor cells (Bagot et al, 1998; Thor Straten et al, 1998).
Also, our recent studies with ¯uorescent in situ hybridization
(FISH) have shown that chromosomal clones can be detected in the
blood of CTCL patients even in the absence of morphologically
identi®able Sezary cells (Karenko et al, 1997).
To reliably identify the membrane markers and cytokines
expressed by the true malignant cells, we have identi®ed these
cells directly in the tissues with in situ hybridization using
chromosome centromere-speci®c probes in combination with
simultaneous immunohistochemical staining. A prerequisite for
this method is the characterization of the chromosomal clone to be
able to select the proper probes. We have modi®ed the FICTION
technique (simultaneous ¯uorescence immunophenotyping and
interphase cytogenetics) of Weber-Matthiesen et al (1992, 1993) by
using new, intense colors visible with a standard (8300) ®lter set,
and, in the study of solid tissue, by using touch preparations instead
of cryosections, which allow the observation of intact, whole cells.
This is the ®rst report of skin studied with such a method and also
the ®rst report where the true malignant cells of CTCL are
identi®ed directly in a tissue with immunophenotyping and
chromosomal markers.
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MATERIALS AND METHODS
Patients and tissue samples The material consisted of tissue samples
obtained from two patients who developed SS and showed a dominant
clone of malignant cells with supernumerary copies of chromosome 8, in
near-diploid or in near-tetraploid cells in blood (Karenko et al, 1999; see
also below). The clones contained also other complex chromosomal
abnormalities, which were partly different in the two patients but remained
remarkably stable during the course of the disease.
Case 1 was a 64-y-old male patient, when he became erythrodermic after
mild psoriasis, localized to elbows, knees, and the scalp. In a skin biopsy
atypical CD4-positive T lymphocytes were seen in the upper dermis but
the biopsy was regarded as nondiagnostic of CTCL because no
epidermotropism was seen. There were 10% of Sezary cells in the blood.
Six months later, enlarged lymph nodes were detected in his left armpit
and, in a biopsy of such a lymph node, nonspeci®c hyperplasia was seen. In
some areas the paracortical area (T zone) was expanded but no de®nite
lymphoma was seen (specimen L 1-1 in the FICTION study). The patient
was then treated with psoralen and ultraviolet A. After an additional 6 mo,
Pautrier's microabscesses were seen in a skin biopsy, and the histologic
diagnosis of MF was made. One month later, 25% of Sezary cells were
found in his blood, and the diagnosis of SS was made (T4N0B1). His
cultivated blood lymphocytes showed 45% of clonally very aberrant mitoses
in G-banding. Further studies showed a gain of chromosome 8 in
comparative genomic hybridization, and supernumerary copies of
chromosome 8 in near-diploid or near-tetraploid cells in FISH (Karenko
et al, 1999). In computerized tomography, enlarged lymph nodes were
detected in armpits and groin. He was then sequentially treated with
etretinate, total skin electron beam irradiation, and cladribine. The disease
progressed, and the treatment was discontinued after 6 mo (18 mo after the
®rst biopsy) because of thrombocytopenia. He died 2 y and 10 mo after the
diagnosis of CTCL. A blood specimen (B 1-1) taken 1 wk before death
showed clonal cells similar to those detected 1 y 10 mo earlier (25 aberrant
out of 25 mitoses after phytohemagglutinin stimulation). This blood sample
and postmortem skin (S 1-1) and lymph node specimens (L 2-1) were used
for the modi®ed FICTION.
Case 2 was a 52-y-old male patient who presented with an eczematous
dermatitis on his soles, ankles, breast, and back. Four months later, a skin
biopsy showed typical histology of MF, and he had 30% of Sezary cells in
peripheral blood (T2N0B1). Clinically, he had patch stage skin lesions, and
he was treated with psoralen and ultraviolet A. Ten months after the
diagnostic skin biopsy, he developed erythrodermia, and the diagnosis of
secondary SS was made. A blood sample showed a near-tetraploid aberrated
mitosis (1 of 100 mitoses), that later was observed to be clonal. Two
months later, his groin lymph nodes were enlarged and showed
histologically dermatopathic lymphonoditis with a slight suspicion of
malignant (T4N1B1) af®sion. This biopsy (L 1-2) was studied with the
modi®ed FICTION. He was then treated with whole body and local
electron beam irradiation (2000 Gy and up to 20 Gy, respectively),
cladribine, and, ®nally, chlorambucil. In blood samples taken 2 y 7 mo after
the diagnosis of MF, and 2 mo thereafter (B 1-2), and in a skin tumor
biopsy taken at the latter time point (S 1-2), very similar cytogenetic or
moleculocytogenetic ®ndings were detected (Karenko et al, 1999). They
included gain of chromosome 8 in comparative genomic hybridization
(blood and skin tumor) and supernumerary copies of its centromere in
FISH both in near-diploid cells and in the last sample also in near-tetraploid
cells (blood). The latter blood (B 1-2) and skin samples (S 1-2) were
examined with the modi®ed FICTION method. The number of Sezary
cells in the latter blood specimen (B 1-2) was 95%, and 95% of
phytohemagglutinin-induced mitoses (19 of 20 mitoses) showed the clonal
aberrations. He died 2 y 10 mo after the diagnosis of MF.
Blood lymphocyte preparations of three healthy, nonsmoking persons
were used as controls. Sections of frozen and formalin-®xed paraf®n-
embedded skin lesion biopsies of one patient with histopathologically
con®rmed lymphomatoid papulosis, and with a favorable course, were
examined for granzyme B positivity (see below).
Preparations and immunohistologic staining Cytospin preparations
of Ficoll-enriched blood mononuclear cells or touch preparates of frozen
skin or lymph node biopsies were ®xed in ice-cold acetone, and an
immunohistologic staining was performed using antibodies to CD3, CD4
(Dako, Glostrup, Denmark), CD45RA (Caltag, Burlingame, CA),
CD45RO, CD8 (Dako), granzyme B, interleukin-2 (IL-2), IL-4, IL-10
(Santa Cruz Biotechnology, Santa Cruz, CA), interferon-g (IFN-g)
(Neomarkers, Fremont, CA), and signaling lymphocytic activation
molecule (SLAM, CDw150; A12 antibody kindly provided by Dr. G.
Aversa, DNAX Research Institute of Molecular and Cellular Biology, Palo
Alto, CA). The primary antibodies were monoclonal mouse antibodies
except for the polyclonal rabbit antibodies against CD3 and IL-2, and goat
antibodies against granzyme B, IL-4, and IL-10. The secondary antibodies
were antirabbit or antimouse goat conjugates of Texas Red X or Alexa 594
R (Molecular Probes, Leiden, The Netherlands), or antirabbit, antigoat, or
antimouse donkey conjugates of Rhodamine Red X (Jackson Immuno
Research Laboratories, West Grove, PA). When necessary, for detection of
weak mouse primary antibodies, Rhodamine Red X conjugate was
followed with antirhodamine rabbit (Molecular Probes) and an antirabbit
donkey conjugate of Rhodamine Red X (Jackson Immuno Research
Laboratories). All antibody layers were preceded by a layer of normal serum
from the animal species, in which the secondary antibody was raised.
Through every step of the process, each slide was accompanied by a similar
control slide with no primary antibody.
In situ hybridization After immunohistologic staining, the samples were
hybridized with a chromosome 8 centromere-speci®c probe
(D8Z2[pJM128]) labeled (Karenko et al, 1997) with a green ¯uorescent
color (Alexa 488, Molecular Probes) or digoxigenin, or a chromosome 1
centromere-speci®c probe (1q12[pUC177]) labeled with biotin (both
probes were kindly provided by Dr. T. Visakorpi, University of Tampere,
Finland). The hybridization was performed as previously described
(Karenko et al, 1997). After posthybridization washes, the biotin-labeled
probes were detected with deglycosylated avidin conjugated with a blue
color (NeutrAvidin conjugated with Alexa 350 or Cascade Blue; Molecular
Probes), followed by biotinylated antiavidin (goat, Vector Laboratories,
Burlingame, CA, or mouse, Sigma, St. Louis, MO), and a new layer of the
same deglycosylated avidin conjugate. The digoxigenin-labeled probes
Table I. Phenotype of cells with clonal chromosomal aberrations (extra copies of chromosomes 1 and 8a) in two patients with
Sezary syndrome
Months after Surface marker
Sample n : o CTCL TCR gene
Tissue - Patient n : o diagnosis rearrangementi CD3 CD4 CD8 CD45RO CD45RA CDw150 Granzyme B
Blood 1-1 34 b +b + -c 75%d 85%d + NDe
1-2 33 b + + ND 85%d dimf ND ND
Skin lesionsg 1-1 34 + + ± + dimf 50%d ±
1-2 33 b. a + + ± + dimf 50%d < 10%e
Lymph node, 1-1 ±6 ND ND ND + + + ±
no lymphoma histology 1-2 12 ND ND ND + + + ±
Lymph node, post mortem 2-1 34 b + + ±c 90%d 90%d + ±
aKarenko et al, 1999, and KaÈhkoÈnen M, personal communication.
bAll clonal cells positive if not otherwise indicated.
cFew weakly positive cells.
dPercentage of clonal cells positive for the marker.
eND, not done.
fWeakly positive cells.
gBoth samples negative for CD30 antigen.
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were detected with sheep antidigoxigenin antibody (Roche Molecular
Biochemicals, Mannheim, Germany), followed by donkey antibody
conjugated with ¯uorescein isothiocyanate (FITC) (Jackson Immuno
Research Laboratories).
Alternative stainings were used to con®rm the results. The immunohis-
tology was performed by detecting the primary mouse antigen with
biotinylated antimouse raised in horse, followed by avidin conjugated with
FITC (Vector Laboratories), and hybridization with a chromosome 8
centromere-speci®c probe labeled with a red color (Alexa 594, Molecular
Probes). Alternatively, the primary mouse antibody was detected with
rabbit antimouse antibody (Sigma), followed by antirabbit raised in swine
(Dako), antiswine raised in rabbit (Rockland, Gilbertsville, PA), and ®nally
goat antirabbit conjugated with a blue color (Alexa 350, Molecular Probes).
The probes used were chromosome 8 centromere-speci®c probe labeled
with Alexa 488 and chromosome-1-speci®c probe labeled with Texas Red
X (colors, Molecular Probes).
The formalin-®xed, paraf®n-embedded skin biopsies of cases 1 and 2
were examined for CD30 and a skin biopsy of the third patient with
lymphomatoid papulosis for granzyme B with the standard immunoper-
oxidase technique (for CD30, StreptABC Complex/HRP kit, Dako,
followed by 3-amino-ethylcarbazole, for granzyme B).2
Analysis and imaging Preparations were analyzed with an ultraviolet
microscope (Olympus BX 50, Tokyo, Japan; equipped with ®lter set 8300
and tripleband exciter 83103x, Chroma Technology, Brattleboro, VT).
Pictures were taken with a cooled CCD camera (Sensi Cam, PCO,
Computer Optics, Kelheim, Germany) connected to a computer (Dell,
Limerick, Ireland; with software Image pro Plus, Media Cybernetics, Silver
Spring, MD).
RESULTS
Immunophenotype of chromosomally clonal cells A
similar and constant phenotype over time was found in
malignant cells with clonal chromosomal aberrations (i.e.,
supernumerary copies of chromosome 8 in near-diploid or
near-tetraploid cells) in the blood, skin, and lymph nodes of
two SS patients (Table I). The malignant cells were CD3 and
CD4 positive but CD8 negative (Table I and Fig 1a±c). Both
CD45RA and CD45RO positivity was observed in the majority
of clonally malignant cells in both patients, although in the
blood of both patients and in the skin of case 2 the staining
with CD45RA was of weaker intensity (Table I, Fig 1d±i). In
the postmortem lymph node of case 1 (L 2-1), both antigens
showed intense staining in the clonal cells (Fig 1d, i).
The lymph node biopsies of both patients obtained before
histologically veri®ed lymphoma involvement showed chromoso-
mally clonal cells in hybridization (25%±35% of the cells in the
touch preparate in L 1-1, and 24%±42%, respectively, in L 1-2). In
both cases, the clonal cells expressed both CD45RA and CD45RO
markers (Table I, Fig 1g).
The CDw150 (SLAM) antigen, characterizing activated memory
T cells (CD45ROhigh) was detected in all tissues of case 1
(Table I). In the skin of both patients, the expression was observed
in about half of the clonal cells (Fig 1j). In contrast to positive
control samples (blood lymphocytes of a healthy person, and the
patient with lymphomatoid papulosis), granzyme-B-positive cells
were observed only occasionally in the skin or lymph node samples
of case 1, and none of these cells represented the malignant clone
(Fig 1k±m). A few (less than 10%) clonal skin cells of case 2
expressed granzyme B very weakly (Table I).
Figure 1. The phenotype of clonal malignant
cells in CTCL is detectable with a modi®ed
FICTION method in blood, skin, and lymph
node samples. Chromosome 8 centromere is vi-
sualized with green ¯uorescence (Alexa 488) in all
panels except for (g), where it is red (Alexa 495).
Chromosome 1 centromere is visualized blue in
(a) and (b), but red in (e). Panels (a)-(e), (g)-(i),
and (l) show tissues of case 1, and (f), (k), and (m)
of case 2. (a) CD3-positive (Texas Red X) clonal
blood cell together with a normal CD3-negative
cell; (b) similar CD-3-positive phenotype of a clo-
nal cell in the lymph node (L 2-1); (c) CD4-posi-
tive (Rhodamine Red X) clonal cells in the skin
shown in two focuses. CD45RO-positive (Texas
Red X) clonal cells along with a normal
CD45RO-negative cell in (d) a lymph node (L 2-
1), (e) the blood (CD45RO dark blue, Alexa 350;
red blood cells stain light blue), and (f) a skin le-
sion (Rhodamine Red X) and (g) a dermatopathic
lymph node (L 1-1, green FITC). CD45RA-posi-
tive (Texas Red X) clonal malignant cells (h) in
the blood along with a normal, CD45RA-nega-
tive cell and (i) in a lymph node (L 2-1) along
with one CD45RA-negative malignant cell and
several normal CD45RA-negative cells. (j)
CDw150/SLAM-positive (Texas Red X) and ne-
gative clonal cells in the blood along with normal
cells. (k) Granzyme-B-negative clonal and normal
cells in a lymph node (L 1-2) with no morpholo-
gic lymphoma involvement; (l) control staining
without antigranzyme antibody (L 1-1), and (m) a
rare granzyme-B-positive cell (Rhodamine Red
X) in a similar lymph node of case 2 (L 1-2). Scale
bars: 10 mm.
2Nevala H, Karenko L, Ranki A: Pro- and antiapoptotic markers in
cutaneous T-cell lymphoma (CTCL) skin in®ltrates and in comparison to
lymphomatoid papulosis. Submitted.
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The cytokine expression The majority of clonal cells expressed
IL-4 (Fig 2). The staining intensity was variable with all colors used
(Rhodamine Red X, Alexa 594 R), showing very bright color
intensities in up to 50% of the clonal cells. At most 20% of the
clonal cells were IL-4 negative (Table II). The majority of the
clonal cells of case 1 were IL-10 negative (Table II), but the
majority of the cells of case 2 were IL-10 positive (Table II, Fig 2).
The majority of the clonal cells of both patients were IL-2 negative
and none expressed IFN-g (Table II, Fig 2). Thus, the cytokine
expression pattern of the clonal cells in skin and lymph node was
IL-2 negative, IL-4 positive, variable for IL-10, and IFN-g
negative.
DISCUSSION
Phenotypically, Sezary cells have been considered to be CD4+,
CD45RA-, CD45RO+, and functionally of Th2 type (Vowels et al,
1992; Saed et al, 1994; Dummer et al, 1996). The cells of our
patients commonly expressed also CD45RA, however, normally
observed in naive T cells (Clement et al, 1988). They also expressed
SLAM (CDw150), which is normally expressed on CD45RO+
peripheral blood memory cells and rapidly upregulated on activated
T cells (Cocks et al, 1995). SLAM directs the immune response
towards the Th0-Th1 pathway (Aversa et al, 1997).
Figure 2. The majority of chromosomally
clonal cells expressed IL-4, and the cells of
case 2 expressed IL-10, but the expression of
IL-2 was rare and no IFN-g was expressed by
the malignant cells. Chromosome 8 centromere
is visualized with green ¯uorescence (FITC) in all
panels except for (h). Panels (a)±(c), (g), and (h)
show lymph node tissue of case 1 (L 2-1), and
(d)±(f), skin tissue of case 2 (S 1-2, all photo-
graphed with color camera). (a) IL-4-positive (red,
Alexa 594) clonal cells together with normal IL-4-
negative cells; (b) a brightly IL-4-positive clonal
cell (red, Alexa 594); (c) control staining without
anti-IL-4 antibody (no red signal); (d) IL-10-posi-
tive (red, Alexa 594) and negative clonal cells; (e)
an IL-2 positive clonal cell (red, Rhodamine Red
X) and IL-2-negative clonal cells; (f) a control
staining without primary antibody; (g) IFN-g-ne-
gative clonal cells; (h) a rare IFN-g-positive cell in
a plain immunostaining of the same tissue as in
(g). Scale bars: 10 mm.
Table II. Chromosomally clonal cells in two patients with Sezary Syndrome expressed IL-4, but the expression of IL-10 was
variable between the patients
Tissue Sample n : o IL-2 IL = 4 IL-10 IFN-gamma
Skin lesion 1-1 +3%a ++50%, +50% +5% NDb
1-2 +2% +80% +80% 0%
Lymph node, post mortem 2-1 +2% ++25%, +75% +8% 0%
a+, positive immunostaining; ++, brightly positive immunostaining.
bND, not done.
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Normally, naive CD45RA+ cells express IL-2, and mature
CD45RO+ cells express IL-4, IL-5, IL-10 (Th2), or IFN-g (Th1).
A strong coexpression of both CD45 isoforms occurs during
transition from CD45RA+ to CD45RO+ (Dbright in ¯ow
cytometry), with expression of IL-2 and IFN-g (LaSalle and
Ha¯er, 1991; Picker et al, 1993; Hamann et al, 1996). Cells with
weaker coexpression of CD45RA/RO (Ddull) express mainly
RO+ type cytokines, IL-4, IL-5, IL-10, or IFN-g, and have been
suggested to represent some stage in T cell differentiation or resting
primed T cells (Hamann et al, 1996). The differentiation of naive to
Th1 or Th2 cells seems to go through a phase where naive cells
express small amounts of IL-4 with IL-2 (Kamogawa et al, 1993;
Bullens et al, 1999). The chromosomally clonal cells of our patients
characteristically expressed IL-4, typical of RO+ type 2 Th cells,
but only in one case (case 2) was IL-10 expression observed.
Despite the variable expression of CDw150, the clonal cells of our
patients did not express IFN-g, usually upregulated by CDw150
(Cocks et al, 1995). Taken together, the phenotype CD45RA+,
CD45RO+, CDw1506, IL-4+, IL-2, IFN-g, and with the
variation in IL-10 expression between the patients, the clonal cells
seem to be intermediate forms between naive CD45RA+ and
CD45RO+ Th2 cells. Possibly, they might represent cells that have
not attained complete maturity, or they could be mature Th2 cells
partly reverted towards a more naive or resting T cell type
(Hamann et al, 1996). The differences in the immunohistologic
staining intensity of IL-4-positive cells must be interpreted with
caution, and the interactions with other cells of the microenviron-
ment were not studied. Our ®nding of malignant cells with the
phenotype CD45RA+, CD45RO+ is in concordance with the
heterogeneity of RA+, RA+/RO+, and RO+ expression between
four SS patients studied with ¯ow cytometry by Urban et al.1
Interestingly, the IL-4 positivity may contribute to the low
frequency of apoptotic cells found in skin lesions of CTCL
patients,2 as IL-4 blocks the action of caspase 3 (Manna and
Aggarwal, 1998), and IL-4-producing T cells have been shown to
be resistant to activation-induced apoptosis (Carbonari et al, 2000).
In contrast to Vermeer et al (1999), who showed cytotoxic T-
lymphocyte-associated granzyme B and cytotoxic-granule-asso-
ciated TIA protein expression in morphologically identi®ed
malignant cells in MF patients, we did not ®nd notable granzyme
B expression in our SS patients in this or our previous study,2
although the sample of lymphomatoid papulosis showed clear
positive staining.
Our ®nding of abundant amounts of malignant chromosomal
clone cells in lymph nodes with dermatopathic lymphonoditis
histology, and obtained even several months prior to malignant
in®ltrate in the skin, suggests that malignant clones may rise
extracutaneously and they may invade lymph nodes early in the
course of the disease. It is noteworthy that the SS of one patient
evolved from MF. The concept of an early systemic nature of
CTCL has gained evidence also from some previous studies
(Whang-Peng et al, 1982; Veelken et al, 1995; Dommann et al,
1996; Trotter et al, 1997; Tok et al, 1998), and early extracutaneous
T cell chromosomal aberrations or T cell clonality have been
veri®ed even in large or small plaque parapsoriasis more recently
(Karenko et al, 1997; Muche et al, 1999). Thus, lymph node
biopsies should be obtained during the early phases of CTCL,
possibly even prior to clinical enlargement, to demonstrate the
presence of malignant cells. A prerequisite for the use of FICTION
in the routine study of lymph nodes or other tissues of CTCL
patients, however, is the de®nition of clonal chromosomal or gene
level aberrations suitable for in situ hybridization for identi®cation
of the malignant clone.
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